LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

44.66 0.63

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

44.19

Max

44.67

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+24.95% upside

Turustatistika
By TradingEconomics
Turukapital	19M 3.2B
Eelmine avamishind	44.03
Eelmine sulgemishind	44.66

Uudiste sentiment

By Acuity

50%

171 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. nov 2025, 15:29 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

China's Jiangxi Copper Rejected by SolGold in $1 Billion Takeover Approach

28. nov 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

28. nov 2025, 19:59 UTC

Market Talk

Oil Futures Settle Lower in Slow Black Friday Trade -- Market Talk

28. nov 2025, 19:47 UTC

Market Talk

U.S. Natural Gas Lifted By Cold Weather Outlook -- Market Talk

28. nov 2025, 18:16 UTC

Market Talk

Global Equities Roundup: Market Talk

28. nov 2025, 18:16 UTC

Market Talk

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28. nov 2025, 18:08 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

28. nov 2025, 18:08 UTC

Market Talk

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28. nov 2025, 17:48 UTC

Market Talk

Bank of Canada May Revise Up Inflation Projections After GDP Data -- Market Talk

28. nov 2025, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

28. nov 2025, 16:50 UTC

Omandamised, ülevõtmised, äriostud

Week's Best: Sieg's Stature at Citi Grows -- Barrons.com

28. nov 2025, 15:51 UTC

Market Talk

Canada Household Spending Edges Lower -- Market Talk

28. nov 2025, 15:33 UTC

Market Talk

Crude Futures Gain as U.S. Market Reopens -- Market Talk

28. nov 2025, 15:21 UTC

Market Talk

Gold Rises on U.S. Rate-Cut Bets After CME Outage -- Market Talk

28. nov 2025, 15:13 UTC

Market Talk

Dollar Recovers Slightly as Investors Already Price in Fed Rate Cut -- Market Talk

28. nov 2025, 15:11 UTC

Market Talk

Global Equities Roundup: Market Talk

28. nov 2025, 15:11 UTC

Market Talk

Canadian National Railway Showing Positive Trend Going Into 2026 -- Market Talk

28. nov 2025, 14:51 UTC

Market Talk

Canada GDP Report Masks Fragile State of Economy -- Market Talk

28. nov 2025, 14:41 UTC

Market Talk

Canada's GDP Level Pulled Higher by 'Eye-Opening' Revisions -- Market Talk

28. nov 2025, 14:37 UTC

Market Talk

U.S. Natural Gas Futures Rise As Temperatures Drop -- Market Talk

28. nov 2025, 14:33 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. nov 2025, 14:33 UTC

Market Talk

Steep Import Drop Fuels Surprise Lift in Canada GDP -- Market Talk

28. nov 2025, 14:20 UTC

Market Talk

Too Much Noise in Canada's Surprise 3Q GDP Gain -- Market Talk

28. nov 2025, 14:10 UTC

Market Talk

Canadian Nowcast Came Closest to Predicting Surprise 3Q Strength -- Market Talk

28. nov 2025, 13:39 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. nov 2025, 13:39 UTC

Market Talk

Canada Trade Data Could Face Larger-Than-Normal Revisions -- Market Talk

28. nov 2025, 13:36 UTC

Market Talk

Canada's Economy Expands More Than Expected -- Market Talk

28. nov 2025, 13:29 UTC

Market Talk

CME Outage Sowing Chaos Across Markets, Trade Nations Says -- Market Talk

28. nov 2025, 13:27 UTC

Market Talk

Russia-Ukraine Peace Efforts to Have Little Impact on Oil Fundamentals -- Market Talk

28. nov 2025, 13:19 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

24.95% tõus

12 kuu keskmine prognoos

Keskmine 55.59 USD 24.95%

Kõrge 65 USD

Madal 44 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

171 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.